Zimmer Biomet extends TMINI deal. Analysts set USD 103.33 for Zimmer Biomet stock

Published on 10/18/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 2.18 billion, up 4.80 percent year over year. Zimmer Biomet stock is due for third-quarter results on November 4, 2026.

Events and valuation markers

Zimmer Biomet extended its TMINI distribution agreement on October 13, 2026.
Second-quarter revenue reached USD 2.18 billion, up 4.80 percent year over year.
Third-quarter results are scheduled for November 4, 2026.
The average analyst target is USD 103.33 from 22 research firms.

Zimmer Biomet US98956P1021 als farbenfrohe Pop-Art-Comic-Szene mit Chirurg und glänzendem Kniegelenkimplantat im OP-Saal, Illustration mit AI erstellt.

Zimmer Biomet extended its exclusive TMINI distribution agreement on October 13, 2026, keeping a wireless handheld robotic system alongside its Persona Knee System. The agreement covers multiple years and gives Zimmer Biomet continued access to a robotic platform for total knee arthroplasty, according to Zimmer Biomet.

Robotics remains the central angle

The extension links Zimmer Biomet's Persona Knee System with THINK Surgical's wireless TMINI system. Management described the arrangement as part of a broader effort to offer surgeons a flexible robotics and enabling-technology ecosystem, while the release said the initial partnership had been successful.

The latest reported operating figures came from the second quarter ended June 30, 2026. Zimmer Biomet generated USD 2.18 billion in revenue, compared with USD 2.09 billion in the first quarter, while net income attributable to common shareholders was USD 198.3 million, according to the company's quarterly data.

Three dated milestones frame the story

On June 30, 2026, second-quarter revenue reached USD 2.18 billion. On October 6, 2026, Zimmer Biomet scheduled its third-quarter results for November 4, 2026, with the release planned for 6:30 a.m. ET and the call for 8:30 a.m. ET, according to Zimmer Biomet. The current event followed on October 13, 2026, when the company extended the TMINI agreement for multiple years.

What does the next report mean?

The November 4 report will test whether the second-quarter growth rate can continue. Zimmer Biomet maintained fiscal 2026 adjusted earnings-per-share guidance of USD 8.47-8.59, while its second-quarter adjusted earnings per share of USD 2.07 exceeded the USD 2.01 consensus estimate, according to MarketBeat.

Dates and valuation markers

Zimmer Biomet's next scheduled reporting date is November 4, 2026. The company also set October 30, 2026, as the payment date for a quarterly dividend of USD 0.24, according to MarketBeat. The average 12-month analyst target is USD 103.33 from 22 firms, including 15 Hold, six Buy and one Sell ratings.

Market value and company profile

Zimmer Biomet had a USD 18.1 billion market capitalization on October 16, 2026. Its NYSE-listed stock closed at USD 94.98 that day, with a 52-week range of USD 79.12 to USD 106.88. The company operates in healthcare and medical devices, designing and manufacturing orthopedic products for joint reconstruction, sports medicine, trauma and related procedures.